Cubist seeks expanded label for Cubicin

Touting a late-stage trial that highlights the effectiveness of Cubicin in reducing heart valve and blood infections caused by Staph bacteria, Cubist Pharmaceuticals says it will ask the FDA for an accelerated review to expand its use. Cubicin is currently approved to prevent skin infections caused by Staph bacteria.

- read this article from the AP for more

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.